Table 1 The relationship between HS-GPS scores and clinicopathological characteristics
variable | HS-GPS 0 | HS-GPS 1 | HS-GPS 2 | P Value | ||||
|---|---|---|---|---|---|---|---|---|
(N = 437) | (N = 107) | (N = 52) | ||||||
Age | (years) | 0.031 | ||||||
< 75 | 313 | 52.7% | 67 | 11.3% | 29 | 4.9% | ||
≥75 | 124 | 20.9% | 38 | 6.4% | 23 | 3.9% | ||
Sex | 0.996 | |||||||
female | 171 | 28.8% | 41 | 6.9% | 20 | 3.4% | ||
male | 266 | 44.8% | 64 | 10.8% | 32 | 5.4% | ||
BMI | 0.016 | |||||||
≥18.5 | 363 | 64.7% | 85 | 15.2% | 42 | 7.5% | ||
< 18.5 | 41 | 7.3% | 20 | 3.6% | 10 | 1.8% | ||
tumor location | 0.084 | |||||||
right side | 178 | 30.0% | 49 | 8.2% | 29 | 4.9% | ||
left side | 259 | 43.6% | 56 | 9.4% | 233.9 | 4.9% | ||
operation approach | 0.001 | |||||||
open | 249 | 42.0% | 78 | 13.2% | 38 | 6.4% | ||
lap | 187 | 31.5% | 27 | 4.6% | 14 | 2.4% | ||
Tumor size T | (cm) | < 0.001 | ||||||
< 5 | 291 | 50.5% | 45 | 7.8% | 11 | 1.9% | ||
≥5 | 134 | 23.3% | 55 | 9.5% | 40 | 5.9% | ||
0.174 | ||||||||
T2/3 | 218 | 36.8% | 56 | 9.4% | 33 | 5.6% | ||
T4 | 218 | 36.8% | 17 | 8.3% | 19 | 3.2% | ||
N | 0.016 | |||||||
N0 | 196 | 33.1% | 67 | 11.3% | 44 | 7.4% | ||
N1/2/3 | 213 | 35.8% | 50 | 8.4% | 24 | 4.0% | ||
CEA | (ng/ml) | 0.621 | ||||||
< 5 | 276 | 51.4% | 66 | 12.3% | 29 | 5.4% | ||
≥5 | 122 | 22.7% | 27 | 5.0% | 17 | 3.2% | ||
CA19–9 | (U/ml) | 0.204 | ||||||
< 37 | 320 | 59.9% | 79 | 14.8% | 29 | 8.1% | ||
≥37 | 79 | 14.8% | 15 | 2.8% | 12 | 2.2% | ||